SOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS Patients
Why now
Thesis: Preclinical funding, no near-term catalyst
Catalyst to watch: Trial initiation or data
Main risk: Therapy may fail in trials
Why it matters
A grant funds early gene-therapy research, which is years from approval and carries no near-term revenue implication.
Details
TOKYO and BOSTON, Sept. 28, 2026 /PRNewswire/ -- SOLA Biosciences Japan GK ("SOLA Japan"), the wholly owned Japanese subsidiary of Boston-based SOLA Biosciences Inc. (together, "SOLA"), announced that it has been awarded a grant of approximately 6 billion yen over five years by the Japan...
Sources
- prnewswire · 2026-09-28 06:00 UTC